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Background:  Acute limb ischemia (ALI) is a morbid event that may result in irreversible tissue loss. We investigated the incidence of ALI in 
a contemporary population of patients with established peripheral artery disease (PAD) and whether it is modified by the PAR-1 antagonist 
vorapaxar.
methods:  TRA2°P-TIMI 50 was a multinational, randomized, double-blind, placebo controlled trial of vorapaxar in stable patients with 
atherosclerosis including 3,787 with symptomatic PAD. ALI was a prespecified adjudicated endpoint using a formal definition. Events 
confirmed as ALI were reviewed to determine the underlying cause and initial treatment.
results:  A total of 109 ALI events occurred during follow up (placebo rate 3.9% at 3 years, 1.3% annualized). The majority of ALI 
events were due to acute surgical graft thrombosis (54%) or in situ thrombosis in a native vessel (27%), while thromboembolism (9%), 
stent thrombosis (8%), and vascular disruption (2%) occurred less frequently (Figure 1a). 43% of patients were treated with surgical 
revascularization, 40% by endovascular intervention, and 17% required amputation (Figure 1b). Overall vorapaxar reduced ALI by 42% 
(2.3%, Hazard Ratio 0.58, p=0.006).
conclusion:  In patients with symptomatic PAD, ALI occurs at a rate of 1.3% per year, is most frequently caused by acute bypass graft 
thrombosis or in situ thrombosis of a diseased vessel, and often results in limb loss. Vorapaxar reduces ALI in patients with symptomatic 
PAD.
 
